Given that Tamoxifen is already a highly promising drug in the treatment of hormone receptor positive breast cancer, further development of Tamoxifen derived tumor-specific boron moieties may offer potential for highly effective, low toxicity BNCT treatments in breast cancer. The gene discussed is NR4A1; the disease is breast cancer.